Percutaneous Renal Sympathetic Denervation: 2013 andBeyond

Canadian Journal of Cardiology

Volumn 30, Issue 1, 2014, Pages 64-74

  Froeschl, Michael ^a   Hadziomerovic, Adnan ^b   Ruzicka, Marcel ^c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CANADA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; KIDNEY DENERVATION; KIDNEY DENERVATION SYSTEM; MEAN ARTERIAL PRESSURE; PERCUTANEOUS RENAL SYMPATHETIC DENERVATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENOVASCULAR HYPERTENSION; REVIEW;

EID: 84890845458     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.11.003     Document Type: Review

References (63)

1. Health Canada. Summary Basis of Decision (SBD) for Symplicity Renal Denervation System. Available at: Accessed May 27,2013. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/md-im/sbd_smd_2012_symplicity_189954-eng.php.
2. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof of principle cohort study. Lancet 2009, 373:1275-1281.
3. Symplicity HTN-2 Investigators, Esler M.D., Krum H., et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010, 376:1903-1909.
4. Symplicity HTN-1 Investigators Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011, 57:911-917.
5. Froeschl M., Hadziomerovic A., Ruzicka M. Renal sympathetic denervation for resistant hypertension. Can J Cardiol 2013, 29:636-638.
6. Bertog S.C., Sobotka P.A., Sievert H. Renal denervation for hypertension. JACC Cardiovasc Interv 2012, 5:249-258.
7. Bunte M.C., Infante de Oliveira E., Shishehbor M.H. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv 2013, 6:1-9.
8. Staessen J.A., Kuznetsova T., Stolarz K. Hypertension prevalence and stroke mortality across populations. JAMA 2003, 289:2420-2422.
9. Robitaille C., Dai S., Waters C., et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ 2012, 184:E49-E56.
10. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774.
11. Tozawa M., Iseki K., Iseki C., et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003, 41:1341-1345.
12. Lim S.S., Vos T., Flaxman A.D., et al. Acomparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
13. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
14. Pimenta E., Calhoun D.A. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012, 125:1594-1596.
15. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
16. de la Sierra A., Segura J., Banegas J.R., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
17. Gee M.E., Bienek A., McAlister F.A., et al. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol 2012, 28:375-382.
18. Daugherty S.L., Powers J.D., Magid D.J., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125:1635-1642.
19. Koepke J.P., DiBona G.F. Functions of the renal nerves. Physiologist 1985, 28:47-52.
20. DiBona G.F., Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010, 298:R245-R253.
21. Smith P.A., Graham L.N., Mackintosh A.F., Stoker J.B., Mary D.A. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004, 17:217-222.
22. Kottke F.J., Kubicek W.G., Visscher M.B. The production of arterial hypertension by chronic renal artery-nerve stimulation. Am J Physiol 1945, 145:38-47.
23. Abramczyk P., Zwolinska A., Oficjalski P., Przybylski J. Kidney denervation combined with elimination of adrenal-renal portal circulation prevents the development of hypertension in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1999, 26:32-34.
24. Page I.H., Heuer G.J. Asurgical treatment of essential hypertension. JClin Invest 1935, 14:22-26.
25. Smithwick R.H., Thompson J.E. Splanchnicectomy for essential hypertension; results in 1266 cases. JAm Med Assoc 1953, 152:1501-1504.
26. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967, 202:1028-1034.
27. Schlaich M., Sobotka P.A., Krum H., Lambert E., Esler M. Renal sympathetic-nerve ablation for uncontrolled hypertension. NEng J Med 2009, 361:932-934.
28. Esler M.D., Krum H., Schlaich M., et al. Renal sympathetic denervation for treatment of drug-resistant hypertension. One-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012, 126:2976-2982.
29. Davis M.I., Filion K.B., Zhang D., et al. Effectiveness of renal denervation therapy for resistant hypertension. JAm Coll Cardiol 2013, 62:231-241.
30. Brandt M.C., Reda S., Mahfoud F., Lenski M., Böhm M., Hoppe U.C. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. JAm Coll Cardiol 2012, 60:1956-1965.
31. Brandt M.C., Mahfoud F., Reda S., et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. JAm Coll Cardiol 2012, 59:901-909.
32. Lambert G.W., Hering D., Esler M.D., et al. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension 2012, 60:1479-1484.
33. Geisler B.P., Egan B.M., Cohen J.T., et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. JAm Coll Cardiol 2012, 60:1271-1277.
34. Esler M., Krum H., Schlaich M., Schmieder R., Böhm M. Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the Symplicity HTN-2 Trial. JClin Hypertens 2013, 15(suppl 1):28.
35. Kline R.L., Mercer P.F. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol 1980, 238:R353-R358.
36. DiBona G.F. Renal innervations and denervation: lessons from renal transplantation reconsidered. Artif Organs 1987, 11:457-462.
37. Burnier M., Wuerzner G., Struijker-Boudier H., Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013, 62:218-225.
38. Ruzicka M, McCormick B, Leenen FHH, Froeschl M, Hiremath S. Adherence to blood pressure lowering drugs and resistant hypertension: should trial of direct observation therapy be part of pre-assessment for renal denervation? Can J Cardiol 2013;29:1741.e1-3.
39. Mahfoud F., Ukena C., Schmieder R.E., et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013, 128:132-140.
40. Persu A., Renkin J., Thijs L., Staessen J.A. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012, 60:596-606.
41. Vaclavik J., Sedlak R., Plachy M., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57:1069-1075.
42. Howard J.P., Nowbar A.N., Francis D.P. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials in 4121 patients with focus on trial design: the CONVERGE report. Heart 2013, 99:1579-1587.
43. Brinkmann J., Heusser K., Schmidt B.M., et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 2012, 60:1485-1490.
44. Hering D., Lambert E.A., Marusic P., et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013, 61:457-464.
45. Fadl Elmula F.E., Hoffmann P., Fossum E., et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013, 62:526-532.
46. Persu A, Jin Y, Azizi M, etal. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2013. [Epub ahead of print].
47. Cook S., Goy J.J., Togni M. Optical coherence findings in renal denervation. Eur Heart J 2012, 33:2992.
48. Kaltenbach B., Id D., Franke J.C., et al. Renal artery stenosis after renal sympathetic denervation. JAm Coll Cardiol 2012, 60:2694-2695.
49. Vonend O., Antoch G., Rump L.C., Blondin D. Secondary rise in blood pressure after renal denervation. Lancet 2012, 380:778.
50. Rippy M.K., Zarins D., Barman N.C., Wu A., Duncan K.L., Zarins C.K. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011, 100:1095-1101.
51. Ukena C., Mahfoud F., Kindedrmann I., et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. JAm Coll Cardiol 2011, 58:1176-1182.
52. Kandzari D.E., Bhatt D.L., Sobotka P.A., et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 Trial. Clin Cardiol 2012, 35:528-535.
53. Davies J.E., Manisty C.H., Petraco R., et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013, 162:189-192.
54. Pokushalov E., Romanov A., Corbucci G., et al. Arandomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. JAm Coll Cardiol 2012, 60:1163-1170.
55. Ukena C., Bauer A., Mahfoud F., et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 2012, 101:63-67.
56. Mahfoud F., Schlaich M., Kindermann I., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
57. Witkowski A., Prejbisz A., Florczak E., et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58:559-565.
58. Streitparth F., Walter A., Stolzenburg N., et al. MR-guided periarterial ethanol injection for renal sympathetic denervation: a feasibility study in pigs. Cardiovasc Intervent Radiol 2013, 36:791-796.
59. Wang Q., Guo R., Rong S., et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. JAm Coll Cardiol 2013, 61:2185-2192.
60. Worthley S.G., Tsioufis C.P., Worthley M.I., et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013, 34:2132-2140.
61. Worthley S.G. EnligHTN-1: Safety and Efficacy of a Novel Multi-Electrode Renal Denervation Catheter in Patients with Resistant Hypertension: A First-In-Human Multicenter Study 2013, EuroPCR, Paris.
62. Mahfoud F., Lüscher T.F., Andersson B., et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013, 34:2149-2157.
63. Schlaich M.P., Schmieder R.E., Bakris G., et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. JAm Coll Cardiol 2013, 62:2031-2045.